RxDoctor Payments Data

Kenneth Lomenzo, MD

Family Medicine · Groesbeck, TXNPI 1861442642

Payments from drug & device makers

$6,593in general payments, 2019–2025

Across 408 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$812
  • Amgen$743
  • AstraZeneca$447
  • Phathom Pharmaceuticals, Inc.$374
  • Otsuka America Pharmaceutical, Inc.$339
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$6,45698%
  • Education$1372%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,593 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$8,710
Medicare patients
21
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide147$179,759
MounjaroTirzepatide68$75,672
JardianceEmpagliflozin44$54,438
RexultiBrexpiprazole30$52,080
EliquisApixaban46$45,957
RybelsusSemaglutide21$45,296
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$36,239
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$29,516
JanuviaSitagliptin Phosphate21$26,880
TrulicityDulaglutide20$25,479
Tresiba Flextouch U-200Insulin Degludec23$20,601
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$19,912
LinzessLinaclotide25$19,462
TradjentaLinagliptin21$12,859
BelsomraSuvorexant11$4,951

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$812$225,056168 claims
Lilly USA, LLCMounjaro, Trulicity$95$101,15088 claims
Boehringer IngelheimJardiance, Tradjenta$134$67,29865 claims
Otsuka America Pharmaceutical, Inc.Rexulti$339$52,08030 claims
PfizerEliquis, Paxlovid$206$47,38657 claims
MerckJanuvia, Belsomra$129$31,83132 claims
GSKTrelegy Ellipta$227$29,51632 claims
AstraZenecaBreztri Aerosphere$447$19,91216 claims
AbbVieLinzess$1,201$19,46225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Groesbeck

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →